| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 552612000 | Three or more oxygens bonded directly to the cyclopentanohydrophenanthrene ring system | 8 |
| 552615000 | Oxygen bonded directly at the 5-, 6- or 7-position | 5 |
| 20090326251 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS - The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors. | 12-31-2009 |
| 20120296105 | CRYSTALLINE ANHYDRATE FORMS OF A PHARMACEUTICAL - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 11-22-2012 |
| 20130066087 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 - The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors. | 03-14-2013 |
| 20150045566 | CRYSTALLINE FORMS OF 5alpha-ANDROSTANE-3beta,5,6beta-TRIOL AND PREPARATION METHODS THEREFOR - The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5α-androstane-3β,5,6β-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2θ values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability. | 02-12-2015 |
| 20160039863 | METHOD FOR PREPARING SUBSTITUTED 3,7-DIHYDROXY STEROIDS - The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β, 7β, 17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors. | 02-11-2016 |
| 552616000 | Oxygen bonded directly at the 16-position | 3 |
| 552617000 | The A ring is a benzene ring (e.g., estriols, etc.) | 3 |
| 20080281112 | Diamine and polyamic acid derived therefrom for liquid crystal orientation applications - A diamine includes a structure of formula (I), | 11-13-2008 |
| 20140235882 | PROCESS FOR THE PREPARATION OF ESTETROL - The present invention relates to a process for the preparation of estra-1,3,5(10)-trien-3,15α,16α,17β-tetraol (estetrol), via a silyl enol ether derivative 17-B-oxy-3-A-oxy-estra-1,3,5(10),16-tetraene, wherein A is a protecting group and B is —Si(R | 08-21-2014 |
| 20140243539 | Process for the Production of Estetrol - The present invention relates to a process for the preparation of a compound of formula (I), hydrates or solvates thereof. | 08-28-2014 |
